Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 127Kidney Neoplasms 39Neoplasms 37Neoplasm Metastasis 35Breast Neoplasms 33Gastrointestinal Stromal Tumors 27Carcinoma, Non-Small-Cell Lung 22Prostatic Neoplasms 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 12Brain Neoplasms 12Pancreatic Neoplasms 11Glioblastoma 11Carcinoma, Hepatocellular 11Melanoma 10Lung Neoplasms 10Stomach Neoplasms 8Neuroendocrine Tumors 8Carcinoma 8Thyroid Neoplasms 7Sarcoma 7Ovarian Neoplasms 7Multiple Myeloma 7Liver Neoplasms 7Small Cell Lung Carcinoma 6Leukemia, Myeloid, Acute 6Glioma 6Esophageal Neoplasms 6Adenoma, Islet Cell 6Uveal Melanoma 5

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2Donepezil 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroectodermal Tumors, Primitive × Sunitinib × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡